Open Heart · 2019 · 46 citations · 28 references
MedicineCardiologyPharmacotherapyImmunotherapyInflammationInterventional CardiologyAcute Coronary Syndrome InterventionAcute Coronary SyndromesAcute InflammationAnti-inflammatory PharmacologyCardiac MedicationsIschemic Heart DiseaseAnti-inflammatory MechanismsInterleukin-6 InhibitionInterleukin-6 InhibitorsMyocardial Ischemia-reperfusion InjuryNon-st-elevation Myocardial InfarctionPost-myocardial Infarction PharmacotherapyTroponin ElevationTroponin Release
Introduction Interleukin-6 (IL-6) may be involved in ischaemia-reperfusion injury and myocardial remodelling after myocardial infarction (MI). We have recently shown that IL-6 inhibition by tocilizumab attenuates systemic inflammation and troponin T-release in patients with acute non-ST elevation MI (NSTEMI). Experimental studies suggest that IL-6 inhibition can limit infarct size through anti-inflammatory mechanisms, but this has not been tested in clinical studies. With the ASS essing the effect of A nti- IL -6 treatment in MI (ASSAIL-MI) trial, we aim to examine whether a single administration of the IL-6 receptor antagonist tocilizumab can increase myocardial salvage in patients with acute ST-elevation MI (STEMI). Methods and analysis The ASSAIL-MI trial is a randomised, double blind, placebo-controlled trial, conducted at three high-volume percutaneous coronary intervention (PCI) centres in Norway. 200 patients with first-time STEMI presenting within 6 hours of the onset of chest pain will be randomised to receive tocilizumab or matching placebo prior to PCI. The patients are followed-up for 6 months. The primary endpoint is the myocardial salvage index measured by cardiac MRI (CMR) 3–7 days after the intervention. Secondary endpoints include final infarct size measured by CMR and plasma markers of myocardial necrosis. Efficacy and safety assessments during follow-up include blood sampling, echocardiography and CMR. Ethics and dissemination Based on previous experience the study is considered feasible and safe. If tocilizumab increases myocardial salvage, further endpoint-driven multicentre trials may be initiated. The ASSAIL-MI trial has the potential to change clinical practice in patients with STEMI. Registration Clinicaltrials.gov, identifier NCT03004703 .
28
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text
Myocardial reperfusion: a double-edged sword?
Eugene Braunwald, Robert A. Kloner · Journal of Clinical Investigation · 1985 · 1.4K citations · Full text
Medicine, Cardiology, Surgery +14
Intracoronary Injection of Mononuclear Bone Marrow Cells in Acute Myocardial Infarction
Ketil Lunde, Svein Solheim, Svend Aakhus et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text
Medicine, Cardiology, Cell Therapy +11
European Society of Cardiology: Cardiovascular Disease Statistics 2017
Adam Timmis, Nick Townsend, Chris P Gale et al. · European Heart Journal · 2017 · 951 citations · Full text
Cyclosporine before PCI in Patients with Acute Myocardial Infarction
Thien-Tri Cung, Olivier Morel, Guillaume Cayla et al. · New England Journal of Medicine · 2015 · 680 citations · Full text